open access

Ahead of print
Review paper
Published online: 2021-04-20
Get Citation

Causes of BIA-ALCL: a summary of the current state of knowledge

Agnieszka Ławnicka, Sławomir Cieśla, Piotr Pluta, Aleksandra Przybylska, Dawid Murawa
DOI: 10.5603/OCP.2021.0013

open access

Ahead of print
REVIEW ARTICLES
Published online: 2021-04-20

Abstract

The reasons for the development of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) have recently been quite a popular topic. The main interest is among plastic surgeons, surgical oncologists, hematologists, and oncologists. Over the past decade, numerous scientific papers on this subject have been published. Potential etiopathogenetic factors include the type of implants, biofilm, inflammation, microtrauma, and genetic mutations. None of the above potential causes have been adequately proven by scientific evidence; anyway, they should not be considered separately, as they are likely to coexist. Further research and exchange of experience among doctors and scientists are necessary to determine the leading etiopathogenetic factor. Its emergence would contribute to the rise of the possibility of using effective preventive measures in patients undergoing breast implant surgery and perhaps even eliminating BIA-ALCL.

Abstract

The reasons for the development of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) have recently been quite a popular topic. The main interest is among plastic surgeons, surgical oncologists, hematologists, and oncologists. Over the past decade, numerous scientific papers on this subject have been published. Potential etiopathogenetic factors include the type of implants, biofilm, inflammation, microtrauma, and genetic mutations. None of the above potential causes have been adequately proven by scientific evidence; anyway, they should not be considered separately, as they are likely to coexist. Further research and exchange of experience among doctors and scientists are necessary to determine the leading etiopathogenetic factor. Its emergence would contribute to the rise of the possibility of using effective preventive measures in patients undergoing breast implant surgery and perhaps even eliminating BIA-ALCL.

Get Citation

Keywords

BIA-ALCL etiological factors; breast implants; breast implant-associated anaplastic large cell lymphoma; complications of oncological and plastic surgery

About this article
Title

Causes of BIA-ALCL: a summary of the current state of knowledge

Journal

Oncology in Clinical Practice

Issue

Ahead of print

Article type

Review paper

Published online

2021-04-20

DOI

10.5603/OCP.2021.0013

Keywords

BIA-ALCL etiological factors
breast implants
breast implant-associated anaplastic large cell lymphoma
complications of oncological and plastic surgery

Authors

Agnieszka Ławnicka
Sławomir Cieśla
Piotr Pluta
Aleksandra Przybylska
Dawid Murawa

References (44)
  1. Hedén P, Stark B. [Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)]. Lakartidningen. 2018; 115.
  2. Miranda RN, Medeiros LJ, Ferrufino-Schmidt MC, et al. Pioneers of Breast Implant-Associated Anaplastic Large Cell Lymphoma: History from Case Report to Global Recognition. Plast Reconstr Surg. 2019; 143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma): 7S–714S.
  3. BIA-ALCL Physician Resources [Internet]. American Society of Plastic Surgeons. https://www.plasticsurgery.org/for-medical-professionals/health-policy/bia-alcl-physician-resources (24.04.2020).
  4. Rastogi P, Deva AK, Prince HM. Breast Implant-Associated Anaplastic Large Cell Lymphoma. Curr Hematol Malig Rep. 2018; 13(6): 516–524.
  5. Collett DJ, Rakhorst H, Lennox P, et al. Current Risk Estimate of Breast Implant-Associated Anaplastic Large Cell Lymphoma in Textured Breast Implants. Plast Reconstr Surg. 2019; 143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma): 30S–40S.
  6. Calobrace MB, Schwartz MR, Zeidler KR, et al. Long-Term Safety of Textured and Smooth Breast Implants. Aesthet Surg J. 2017; 38(1): 38–48.
  7. Allergan Recalls Natrelle Biocell Textured Breast Implants Due to Risk of BIA-ALCL Cancer [Internet]. US FOOD&DRUG ADMINISTRATION. https://www.fda.gov/medical-devices/medical-device-recalls/allergan-recalls-natrelle-biocell-textured-breast-implants-due-risk-bia-alcl-cancer (24.04.2020).
  8. General and Plastic Surgery Devices Panel March 25-26, 2019 Mentor Briefing Package[Internet]. US FOOD&DRUG ADMINISTRATION. https://www.fda.gov/media/123013/ (24.04.2020).
  9. Peters W, Young V, Jerina K. Biomaterials in Plastic Surgery: Breast Implants. Woodhead Publishing 2012: 98.
  10. Hamdi M. Association Between Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk and Polyurethane Breast Implants: Clinical Evidence and European Perspective. Aesthet Surg J. 2019; 39(Suppl_1): S49–S54.
  11. Magnusson M, Beath K, Cooter R, et al. The Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand Confirms the Highest Risk for Grade 4 Surface Breast Implants. Plast Reconstr Surg. 2019; 143(5): 1285–1292.
  12. Blombery P, Thompson ER, Jones K, et al. Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma. Haematologica. 2016; 101(9): e387–e390.
  13. O'Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015; 66: 311–328.
  14. Thomas SJ, Snowden JA, Zeidler MP, et al. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer. 2015; 113(3): 365–371.
  15. Oishi N, Miranda RN, Feldman AL. Genetics of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Aesthet Surg J. 2019; 39(Suppl_1): S14–S20.
  16. Gristina AG. Biomaterial-centered infection: microbial adhesion versus tissue integration. Science. 1987; 237(4822): 1588–1595.
  17. Chagnot C, Zorgani MA, Astruc T, et al. Proteinaceous determinants of surface colonization in bacteria: bacterial adhesion and biofilm formation from a protein secretion perspective. Front Microbiol. 2013; 4: 303.
  18. Habimana O, Semião A, Casey E. The role of cell-surface interactions in bacterial initial adhesion and consequent biofilm formation on nanofiltration/reverse osmosis membranes. Journal of Membrane Science. 2014; 454: 82–96.
  19. Rochford ETJ, Richards RG, Moriarty TF. Influence of material on the development of device-associated infections. Clin Microbiol Infect. 2012; 18(12): 1162–1167.
  20. Tieszer C, Reid G, Denstedt J. Conditioning film deposition on ureteral stents after implantation. J Urol. 1998; 160(3 Pt 1): 876–881.
  21. Costerton JW, Montanaro L, Arciola CR. Biofilm in implant infections: its production and regulation. Int J Artif Organs. 2005; 28(11): 1062–1068.
  22. Jacombs A, Tahir S, Hu H, et al. In vitro and in vivo investigation of the influence of implant surface on the formation of bacterial biofilm in mammary implants. Plast Reconstr Surg. 2014; 133(4): 471e–480e.
  23. Hu H, Jacombs A, Vickery K, et al. Chronic biofilm infection in breast implants is associated with an increased T-cell lymphocytic infiltrate: implications for breast implant-associated lymphoma. Plast Reconstr Surg. 2015; 135(2): 319–329.
  24. Hu H, Johani K, Almatroudi A, et al. Bacterial Biofilm Infection Detected in Breast Implant-Associated Anaplastic Large-Cell Lymphoma. Plast Reconstr Surg. 2016; 137(6): 1659–1669.
  25. Clemens MW, DeCoster RC, Fairchild B, et al. Finding Consensus After Two Decades of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Semin Plast Surg. 2019; 33(4): 270–278.
  26. Sorotos M, Longo B, Amorosi V, et al. Macrotextured Breast Implants with Defined Steps to Minimize Bacterial Contamination around the Device: Experience in 42,000 Implants. Plast Reconstr Surg. 2018; 142(3): 412e–413e.
  27. Ryan MP, Adley CC. The antibiotic susceptibility of water-based bacteria Ralstonia pickettii and Ralstonia insidiosa. J Med Microbiol. 2013; 62(Pt 7): 1025–1031.
  28. Wee AT, Morrey BF, Sanchez-Sotelo J. The fate of elbows with unexpected positive intraoperative cultures during revision elbow arthroplasty. J Bone Joint Surg Am. 2013; 95(2): 109–116.
  29. Ryan MP, Adley CC. Ralstonia spp.: emerging global opportunistic pathogens. Eur J Clin Microbiol Infect Dis. 2014; 33(3): 291–304.
  30. Coussens L, Werb Z. Inflammation and cancer. Nature. 2002; 420(6917): 860–867.
  31. Stefanko E, Wróbel T. Etiopatogeneza infekcyjna chłoniaków. Hematol. 2010(1): 288–295.
  32. Kadin ME, Deva A, Xu H, et al. Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Aesthet Surg J. 2016; 36(7): 773–781.
  33. Bizjak M, Selmi C, Praprotnik S, et al. Silicone implants and lymphoma: The role of inflammation. J Autoimmun. 2015; 65: 64–73.
  34. Handel N, Gutierrez J. Long-term safety and efficacy of polyurethane foam-covered breast implants. Aesthet Surg J. 2006; 26(3): 265–274.
  35. Brody GS. The Case against Biofilm as the Primary Initiator of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Plast Reconstr Surg. 2016; 137(4): 766e–767e.
  36. Clemens MW, Nava MB, Rocco N, et al. Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules. Gland Surg. 2017; 6(2): 169–184.
  37. Kaartinen I, Sunela K, Alanko J, et al. Breast implant-associated anaplastic large cell lymphoma - From diagnosis to treatment. Eur J Surg Oncol. 2017; 43(8): 1385–1392.
  38. Wise LA, Palmer JR, Boggs DA, et al. Abuse victimization and risk of breast cancer in the Black Women's Health Study [corrected]. Cancer Causes Control. 2011; 22(4): 659–669.
  39. Rigby JE, Morris JA, Lavelle J, et al. Can physical trauma cause breast cancer? Eur J Cancer Prev. 2002; 11(3): 307–311.
  40. Kuraishy A, Karin M, Grivennikov SI. Tumor promotion via injury- and death-induced inflammation. Immunity. 2011; 35(4): 467–477.
  41. Center for Devices and Radiological Health [Internet]. U.S. Food and Drug Administration. Anaplastic large cell lymphoma (ALCL) in women with breast implants: preliminary FDA findings and analysis. http://www.fda.gov/downloads/MedicalDevices/ProductsandMedicalProcedures/Implant- sandProsthetics/BreastImplants/UCM240003 (24.04.2020).
  42. Pupka D, Sawicki T, Sikora J, et al. Zakażenie miejsca operowanego – postępowanie. Chirurgia po Dyplomie. 2019; 02.
  43. Cordeiro PG, Ghione P, Ni A, et al. Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants. J Plast Reconstr Aesthet Surg. 2020; 73(5): 841–846.
  44. Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04220970 (24.10.2020).

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl